Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Combined Mass Spectrometry System

By Drug Discovery Trends Editor | June 8, 2009

BioTrove, Inc. presented data at the 57th American Society for Mass Spectrometry Conference on Mass Spectrometry in Philadelphia, Pennsylvania demonstrating the compatibility of its RapidFire Mass Spectrometry (RF-MS) system with Agilent Technologies Inc.’s Time-of-Flight (TOF) mass spectrometer system for high-throughput screening of protein inhibitors and examination of drug-drug interaction assays. Combining the two platforms, drug discovery researchers can now perform high-throughput drug-drug interaction and label-free kinase assays using whole protein substrates.

These data were presented by Drs. William A. LaMarr and Michelle V. Romm. Dr. LaMarr showed that the RapidFire/Time-of-Flight system provides researchers accurate mass data for high-throughput analysis of CYP inhibition assays. The use of accurate mass measurements afforded by the Agilent TOF-MS has the potential to streamline the workflow in other in vitro ADME applications such as metabolic stability assays by eliminating the bottleneck of MS method development.

Dr. Romm’s presentation demonstrated that the RapidFire/Time-of-Flight system provides a high-throughput screening interface for the label-free detection of whole protein kinase activity at per sample throughputs under 10 seconds. The ability to use whole protein substrates in kinase assays enables researchers to investigate challenging kinase targets, such as those that have multiple phosphorylation sites or kinases that auto-phosphorylate, that are problematic to study with optical or radiometric assay formats.

The integration of RapidFire with Agilent’s state-of-the-art Time-of-Flight technology provides scientists a new tool to accelerate and expand on possibilities in drug discovery and disease research. These combined technologies provide scientists an end-to-end solution for high-throughput drug discovery and ADME screening.

The RapidFire/Time-of-Flight system allows for the analysis of whole proteins in their native state, rather than fragmented peptide substrates, including methylases and demethylases, ubiquitinases, acetylases and deacetylases, kinases, and phosphatases.

Source: Biotrove 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50